Natera
NTRA Large CapHealthcare · Diagnostics & Research
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Natera en bref
Natera (NTRA) is currently trading at 232,69 € with a market capitalization of 33,3 Md €. The 52-week range spans from 115,59 € to 250,32 €; the current price is 7% below the yearly high. Year-over-year revenue growth stands at +38.8%.
💰 Dividende
Natera currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
21 analystes évaluent Natera (NTRA) au consensus : Achat Fort. L'objectif de cours moyen est de 245,82 €, soit un potentiel de +5.64% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 167,72 € à 286,78 €.
Natera : la thèse d'investissement en détail
Natera (NTRA) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 38.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 65.07%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
Signal Smart Money
On the institutional side, Natera appears in the disclosed holdings of Druckenmiller. Smart-money managers track positioning, fundamentals and competitive dynamics with research budgets few retail investors can match — when several converge on the same name, it is rarely random. That doesn't mean blind copying makes sense, but it does raise the bar for the bear case.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 38.8% sur un an
- Marge brute élevée de 65.07% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 13.53)
- Free cash flow positif
- –Actuellement non rentable
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to market-like volatility.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Natera?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
